Insight

Stephen V Liu on Phase 2 Study of Irinotecan plus Anlotinib for Platinum-Resistant SCLC

Stephen V Liu/X

Jun 25, 2025, 09:00

Stephen V Liu on Phase 2 Study of Irinotecan plus Anlotinib for Platinum-Resistant SCLC

Stephen V Liu, Director of Thoracic Oncology and Associate Professor of Medicine at Georgetown University, shared a post on X:

“Single arm phase II study of irinotecan + anlotinib for platinum-resistant SCLC published Lung Cancer Journal (n=37). RR 62%, PFS 4.5m, OS 7.2m.

Tarlatamab is the standard here but still need novel agents. Always hard to interpret single arm SCLC studies.”

Title: Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study

Journal: Lung Cancer Journal

Article: Minna Zhang, Yi Tang, Jiafeng Liang, Lucheng Zhu, Bing Wang, Kaicheng Pan, Xiao Xu, Xueqin Chen, Bing Xia

Read the full article.

Stephen V Liu

More posts featuring Stephen V Liu on OncoDaily.

Bing Wang Bing Xia cancer Jiafeng Liang Kaicheng Pan Lucheng Zhu Lung Cancer Journal Minna Zhang OncoDaily Oncology SCLC Stephen V Liu Xiao Xu Xueqin Chen Yi Tang

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care